Buy Hold Sell: 5 resilient cash cows

Here at Livewire, we are fortunate enough to speak with the country's top investors every day. And if there is one recommendation these pros have consistently repeated in what has become a tumultuous year of rising interest rates, it's the importance of investing in stocks with tangible and growing profits.

Unlike their long-duration counterparts, stocks earning a nice clip in the here and now have managed to be quite resilient in an otherwise volatile year.

So in this episode, Livewire's Ally Selby was joined by Medallion Financial's Michael Wayne and Hayborough Investment Partners' Ben Rundle for their analysis of three profitable ASX darlings.

Plus, they also bring along one small cap that they believe will continue to spew out cash (and remain resilient) over the year ahead.

Note: This episode was filmed on Wednesday 12th October 2022. You can read an edited transcript below:

Timecodes:
0:00 - Intro
0:31 - Is Pro Medicus (ASX: PME) a buy, hold or sell?
2:10 - Is OFX Group (ASX: OFX) a buy, hold or sell?
3:37 - Is Lovisa (ASX: LOV) a buy, hold or sell?
5:18 - Michael's resilient stock pick for the year ahead
6:31 - Ben's resilient stock pick for the year ahead

[dehaka]

i think PME is a sell because of the bond yields. i just don't understand how stocks like PME, CSL, are valued, with these bond yields they should be much much lower than today's price. clearly market hasn't updated the discount rate for these darlings.

PME the company is absolutely top notch, my negative sentiment is purely due to bond yields.